Search

Your search keyword '"Casanova, M."' showing total 1,935 results

Search Constraints

Start Over You searched for: Author "Casanova, M." Remove constraint Author: "Casanova, M."
1,935 results on '"Casanova, M."'

Search Results

51. Urban billabong restoration benefits from Traditional Owner involvement and regular flooding

55. Towards Non-invasive Image-Based Early Diagnosis of Autism

56. Supplementary Methods and References from A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer

57. Supplementary Tables S1-S7 from A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer

59. P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding

60. P036 Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profiles

61. P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

62. OP27 Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU

63. P541 Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study

64. P327 Characteristics of esophago-gastro-duodenal Crohn's disease in the biologic era: a nationwide study of the Young GETECCU Group

65. P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry

66. DOP82 Biological Treatment Cycles in Crohn’s Disease

67. P386 Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study

68. P106 Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach

69. P049 Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease

70. P044 Ex vivo effects of infliximab on the long non-coding RNAs expression levels in Crohn′s disease

74. Percepción y prioridades respecto al proceso de consentimiento informado quirúrgico; un análisis mediante métodos mixtos.

78. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study

80. Towards a high-precision measurement of the 3He(α, γ)7Be cross section at LUNA

82. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE

84. Ocular Morphologic Traits in the American Cocker Spaniel May Confer Primary Angle Closure Glaucoma Susceptibility

86. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

87. DOP016 Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study

90. DOP78 Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

91. P519 Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease

92. P289 Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project

93. P545 Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU

94. P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

95. P018 Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery

96. P027 Effects of anti-TNF and anti-α4β7 drugs on circulating monocytes migratory capacity in inflammatory bowel disease

97. P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU

98. Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma

100. Clinical presentation, treatment, and genetic and histopathological analysis of juvenile cataracts and secondary glaucoma in a rhesus macaque ( Macaca mulatta )

Catalog

Books, media, physical & digital resources